Oscar Health took a major hit this year due to ACA-related votes and sector headwinds, leading to sharp price declines.
The stock broke its downtrend aggressively, signaling strong momentum, although the pullback has also been volatile.
Oscar currently trades far below its estimated fair value of $18–$20, making the price look attractive for a recovery.
For bullish confirmation, I want to see clear closes above $17 – the 50% Fibonacci retracement between the wave 1 high and wave 2 low. Only then would I expect wave 3 to be underway.
Without this technical confirmation, my bias remains neutral.
The stock broke its downtrend aggressively, signaling strong momentum, although the pullback has also been volatile.
Oscar currently trades far below its estimated fair value of $18–$20, making the price look attractive for a recovery.
For bullish confirmation, I want to see clear closes above $17 – the 50% Fibonacci retracement between the wave 1 high and wave 2 low. Only then would I expect wave 3 to be underway.
Without this technical confirmation, my bias remains neutral.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。